HomeCompareGFED vs ABBV

GFED vs ABBV: Dividend Comparison 2026

GFED yields 29.62% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GFED wins by $39199777.02M in total portfolio value
10 years
GFED
GFED
● Live price
29.62%
Share price
$31.43
Annual div
$9.31
5Y div CAGR
86.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$39199777.13M
Annual income
$38,689,530,059,543.64
Full GFED calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — GFED vs ABBV

📍 GFED pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGFEDABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GFED + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GFED pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GFED
Annual income on $10K today (after 15% tax)
$2,517.34/yr
After 10yr DRIP, annual income (after tax)
$32,886,100,550,612.09/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, GFED beats the other by $32,886,100,529,556.09/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GFED + ABBV for your $10,000?

GFED: 50%ABBV: 50%
100% ABBV50/50100% GFED
Portfolio after 10yr
$19599888.61M
Annual income
$19,344,765,042,157.70/yr
Blended yield
98.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

GFED
Analyst Ratings
1
Buy
Consensus: Buy
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GFED buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGFEDABBV
Forward yield29.62%3.06%
Annual dividend / share$9.31$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR86.3%40.6%
Portfolio after 10y$39199777.13M$102.3K
Annual income after 10y$38,689,530,059,543.64$24,771.77
Total dividends collected$39165669.31M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: GFED vs ABBV ($10,000, DRIP)

YearGFED PortfolioGFED Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$16,217$5,517.41$11,550$430.00+$4.7KGFED
2$32,932$15,579.21$13,472$627.96+$19.5KGFED
3$90,319$55,081.93$15,906$926.08+$74.4KGFED
4$359,669$263,027.62$19,071$1,382.55+$340.6KGFED
5$2,208,549$1,823,703.68$23,302$2,095.81+$2.19MGFED
6$21,861,034$19,497,886.34$29,150$3,237.93+$21.83MGFED
7$359,422,959$336,031,652.72$37,536$5,121.41+$359.39MGFED
8$10,003,902,648$9,619,320,081.11$50,079$8,338.38+$10003.85MGFED
9$476,866,418,368$466,162,242,534.98$69,753$14,065.80+$476866.35MGFED
10$39,199,777,127,197$38,689,530,059,543.64$102,337$24,771.77+$39199777.02MGFED

GFED vs ABBV: Complete Analysis 2026

GFEDStock

Guaranty Federal Bancshares, Inc. operates as the bank holding company for Guaranty Bank that provides a range of banking and mortgage services to individual and corporate customers in southwest Missouri. The company's deposit products include checking accounts, money market accounts, savings accounts, fixed-term certificates of deposit, and individual retirement accounts, as well as demand deposits and NOW accounts. Its loan portfolio comprises commercial real estate loans, one-to four-family mortgage loans, multi-family residential mortgage loans, and construction loans, as well as agriculture, small business administration, and business loans; and consumer and other loans, such as loans secured by certificates of deposit, automobiles, recreational vehicles, boat loans, and home equity loans. The company also invests in mortgage-backed securities, U.S. Government and federal agency securities, and other marketable securities. As of January 20, 2022, it had 16 full-service branches in Greene, Christian, Jasper, and Newton counties; a loan production office in Webster County; and approximately 37,000 ATMs. Guaranty Federal Bancshares, Inc. was founded in 1913 and is based in Springfield, Missouri.

Full GFED Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this GFED vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GFED vs SCHDGFED vs JEPIGFED vs OGFED vs KOGFED vs MAINGFED vs JNJGFED vs MRKGFED vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.